Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
Compass Therapeutics
Eli Lilly and Company
Kivu Bioscience Inc.
Astellas Pharma Inc
Kestrel Therapeutics, Inc.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eli Lilly and Company
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Plexium, Inc.
Deciphera Pharmaceuticals, LLC
Revolution Medicines, Inc.
USWM, LLC (dba US WorldMeds)
Conjupro Biotherapeutics, Inc.
Alterome Therapeutics, Inc.
IDEAYA Biosciences
National Institutes of Health Clinical Center (CC)
Pfizer
Eli Lilly and Company
Aptamer Sciences, Inc.
Eli Lilly and Company
National Cancer Institute (NCI)
GlaxoSmithKline
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Institut Paoli-Calmettes
Orano Med LLC
Conjupro Biotherapeutics, Inc.
Mayo Clinic
Stanford University
Boehringer Ingelheim
Eli Lilly and Company
Fred Hutchinson Cancer Center
Tomsk National Research Medical Center of the Russian Academy of Sciences
Ankyra Therapeutics, Inc
Daiichi Sankyo
ViroMissile, Inc.
Pfizer
IntoCell, Inc
Pfizer
Tizona Therapeutics, Inc
InSilico Medicine Hong Kong Limited
ALX Oncology Inc.
Clasp Therapeutics, Inc.
Genentech, Inc.
NiKang Therapeutics, Inc.
Werewolf Therapeutics, Inc.
MacroGenics
Nanjing Sanhome Pharmaceutical, Co., Ltd.
Prelude Therapeutics
Royal Marsden NHS Foundation Trust